MA53390A - Procédés d'utilisation d'un co-agoniste de gip/glp1 pour une thérapie - Google Patents

Procédés d'utilisation d'un co-agoniste de gip/glp1 pour une thérapie

Info

Publication number
MA53390A
MA53390A MA053390A MA53390A MA53390A MA 53390 A MA53390 A MA 53390A MA 053390 A MA053390 A MA 053390A MA 53390 A MA53390 A MA 53390A MA 53390 A MA53390 A MA 53390A
Authority
MA
Morocco
Prior art keywords
glp1
gip
agonist
therapy
methods
Prior art date
Application number
MA053390A
Other languages
English (en)
Inventor
Charles T Benson
Axel Haupt
Melissa Kay Thomas
Shweta Urva
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA53390A publication Critical patent/MA53390A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA053390A 2018-07-23 2019-07-22 Procédés d'utilisation d'un co-agoniste de gip/glp1 pour une thérapie MA53390A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862702061P 2018-07-23 2018-07-23
US201862730565P 2018-09-13 2018-09-13
US201862740619P 2018-10-03 2018-10-03

Publications (1)

Publication Number Publication Date
MA53390A true MA53390A (fr) 2021-06-02

Family

ID=68387389

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053390A MA53390A (fr) 2018-07-23 2019-07-22 Procédés d'utilisation d'un co-agoniste de gip/glp1 pour une thérapie

Country Status (15)

Country Link
US (2) US20200023040A1 (fr)
EP (1) EP3826716A1 (fr)
JP (2) JP2021533094A (fr)
KR (1) KR20210024583A (fr)
CN (1) CN112512633A (fr)
AU (2) AU2019309796B2 (fr)
BR (1) BR112020026372A2 (fr)
CA (1) CA3107344A1 (fr)
IL (1) IL280258A (fr)
MA (1) MA53390A (fr)
MX (1) MX2021000794A (fr)
SG (1) SG11202100112YA (fr)
TW (1) TWI842722B (fr)
UA (1) UA128697C2 (fr)
WO (1) WO2020023382A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022510691A (ja) 2018-12-05 2022-01-27 バイキング・セラピューティクス・インコーポレイテッド 線維症及び炎症の処置のための組成物
CN110642935A (zh) * 2019-09-25 2020-01-03 成都奥达生物科技有限公司 一种替瑞帕肽类似物
TW202140058A (zh) * 2020-01-30 2021-11-01 美商美國禮來大藥廠 提派肽(tirzepatide)之治療用途
MX2023000303A (es) 2020-07-22 2023-02-09 Novo Nordisk As Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral.
MX2023008330A (es) * 2021-01-20 2024-01-18 Viking Therapeutics Inc Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos.
WO2022177744A1 (fr) * 2021-02-17 2022-08-25 Eli Lilly And Company Procédés thérapeutiques agonistes doubles gip/glp1
EP4358951A1 (fr) * 2021-06-25 2024-05-01 Eli Lilly and Company Méthodes de traitement de l'apnée obstructive du sommeil
KR20240136386A (ko) * 2022-01-18 2024-09-13 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 장애 치료를 위한 약학 제제 및 방법
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
WO2024006662A1 (fr) * 2022-06-30 2024-01-04 Eli Lilly And Company Compositions de tirzepatide et leur utilisation
WO2024059480A2 (fr) * 2022-09-12 2024-03-21 Eli Lilly And Company Gip/glp1 destiné à être utilisé en thérapie

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8734394B2 (en) 2010-03-01 2014-05-27 Eli Lilly And Company Automatic injection device with delay mechanism including dual functioning biasing member
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
TWI705820B (zh) * 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物

Also Published As

Publication number Publication date
JP2021533094A (ja) 2021-12-02
CN112512633A (zh) 2021-03-16
UA128697C2 (uk) 2024-10-02
TW202019460A (zh) 2020-06-01
BR112020026372A2 (pt) 2021-03-23
CA3107344A1 (fr) 2020-01-30
SG11202100112YA (en) 2021-02-25
IL280258A (en) 2021-03-01
AU2022291585B2 (en) 2024-08-15
MX2021000794A (es) 2021-04-12
TWI842722B (zh) 2024-05-21
US20210338781A1 (en) 2021-11-04
KR20210024583A (ko) 2021-03-05
AU2019309796B2 (en) 2022-10-13
WO2020023382A1 (fr) 2020-01-30
JP2022130686A (ja) 2022-09-06
AU2019309796A1 (en) 2021-01-21
AU2022291585A1 (en) 2023-02-02
EP3826716A1 (fr) 2021-06-02
US20200023040A1 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
MA53390A (fr) Procédés d'utilisation d'un co-agoniste de gip/glp1 pour une thérapie
IL279827A (en) GIP/GLP1 co-agonist compounds
UA41384S (uk) Зарядне пристосування для прибирального пристрою
MA45783A (fr) Procédés d'évaluation de la présence ou de l'absence d'un virus compétent pour la réplication
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
DK3702023T3 (da) Skråtstillet blandeapparat
PL3864238T3 (pl) Urządzenie do zacierania betonu
MA53378A (fr) Procédé d'utilisation d'un co-agoniste de gip/glp1 contre le diabète
GB201907862D0 (en) A method of determining a route
MA52545A (fr) Anticorps pour radionucléides chélatés
MA45047A (fr) Procédés d'utilisation d'inhibiteurs de fasn
DE102020112518B8 (de) Toner
DK3774246T3 (da) Apparat til fremstilling af mindst en tredimensional komponent til byggeindustrien
GB201813169D0 (en) Underwater navigation
DK3816247T3 (da) Hærderblanding
MA55373A (fr) Procédé pour équilibrer dynamiquement un corps rotatif
DK3712354T3 (da) Forskallingsplatform
MA53648A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase
HUP1800247A1 (hu) Extracelluláris vezikulák mennyiségének meghatározására kidolgozott új módszer
FR3039824B1 (fr) Kit pour le guidage d'une turbomachine d'aeronef pendant sa pose / depose le long d'un berceau
GB2591004B (en) Concrete washout system
MA53565A (fr) Procédés d'utilisation d'un composé phénoxypropylamine pour le traitement de la douleur
MA56190A (fr) Dosage modifié de tocilizumab sous-cutané pour la polyarthrite rhumatoïde
MA55531A (fr) Procédés pour le traitement de béta-thalassémie
MA55550A (fr) Auto-injecteur pour injections